International Workshop “Developing New Models for Pharmaceutical Innovation: towards a Mixed Economy”
10:30 to 17:00 CET
Monday 15 July 2024
Schipluidenlaan 4, Amsterdam, and online
Dear colleagues,
We are delighted to invite you to an international workshop on Developing New Models for Pharmaceutical Innovation: towards a Mixed Economy. This will be held in Amsterdam on Monday 15 July and will bring together key international organisations, policy makers, scholars, clinicians, patients, SME pharma representatives, and other involved practitioners to discuss alternative, collaborative ways of developing new medicines.
We are delighted to have a number of great speakers already confirmed, including , , , , , , and Roz Scourse from - and there are more to come!
Several initiatives in the public and non-profit sectors seek new ways of discovering, developing, and manufacturing a broad range of medicines and medical products. These initiatives include repurposing (generic) drugs, collaborative platforms, public-private partnerships, patient and clinician-led development of medicines, and public-sector manufacturing. They often target tropical diseases, (ultra) rare conditions, and other areas of high need, such as anti-microbial resistance.
The idea of a "mixed economy of pharmaceutical innovation" highlights these alternative models, multiple systems, and different economies complementary to the 'mainstream' pharmaceutical industry. These initiatives do not directly compete with industry in creating novel therapies but primarily seek to ensure access to medicines for all.
Public policy should actively support the creation of alternative models, sometimes labelled 'social pharmaceutical innovations' (SPINs), and thus advance a mixed economy. Developing such policies requires a focused discussion of critical issues, including:
1) Funding – developing new models of circular or sustainable funding for non-profit or low-margin commercial innovation is critical to support a vibrant third sector. How can we go beyond a reliance on philanthropy and government research funding in the long run?
2) Procurement – many health care systems have rigid policies on drug pricing that make it hard to differentially price repurposed drugs or support public sector manufacturing. What new payment systems could be introduced to support alternative innovation models?
3) Regulation – there are many regulatory barriers to non-commercial actors holding marketing authorisation or supporting late-stage drug development. These barriers include liability and data collection concerns. What novel institutional mechanisms may address these issues?
4) Collaboration – new models of innovation require important changes in the relationship between the public/non-profit and private sectors in the division of responsibilities and benefit sharing. How can a new social contract be negotiated that supports public health-driven innovation whilst incentivising private investment in lower-cost drug development?
This workshop is supported by , , and and sponsored by , , iHuman, University of 91̽, and .
The event has already sparked a great deal of interest and we expect it to be oversubscribed, so we encourage you to register soon. This can be done via: .
For more information please contact Tineke (tineke.kleinhout-vliek@ucd.ie) or Paul (paul.martin@sheffield.ac.uk). We look forward to seeing you in Amsterdam!
Best wishes,
Tineke Kleinhout-Vliek, University College Dublin~
Paul Martin, University of 91̽
Wouter Boon, Utrecht University
